| Literature DB >> 33838082 |
Tim J Wigle1, Yue Ren1, Jennifer R Molina1, Danielle J Blackwell1, Laurie B Schenkel1, Kerren K Swinger1, Kristy Kuplast-Barr1, Christina R Majer1, W David Church1, Alvin Z Lu1, Jason Mo1, Ryan Abo1, Anne Cheung1, Bryan W Dorsey1, Mario Niepel1, Nicholas R Perl1, Melissa M Vasbinder1, Heike Keilhack1, Kevin W Kuntz1.
Abstract
PARP14 is an interferon-stimulated gene that is overexpressed in multiple tumor types, influencing pro-tumor macrophage polarization as well as suppressing the antitumor inflammation response by modulating IFN-γ and IL-4 signaling. PARP14 is a 203 kDa protein that possesses a catalytic domain responsible for the transfer of mono-ADP-ribose to its substrates. PARP14 also contains three macrodomains and a WWE domain which are binding modules for mono-ADP-ribose and poly-ADP-ribose, respectively, in addition to two RNA recognition motifs. Catalytic inhibitors of PARP14 have been shown to reverse IL-4 driven pro-tumor gene expression in macrophages, however it is not clear what roles the non-enzymatic biomolecular recognition motifs play in PARP14-driven immunology and inflammation. To further understand this, we have discovered a heterobifunctional small molecule designed based on a catalytic inhibitor of PARP14 that binds in the enzyme's NAD+ -binding site and recruits cereblon to ubiquitinate it and selectively target it for degradation.Entities:
Keywords: ADP-ribosylation; IL-4; PARP14; degrade; macrophages
Mesh:
Substances:
Year: 2021 PMID: 33838082 DOI: 10.1002/cbic.202100047
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164